Cancer ResearchPersonalized Neoantigen Cancer Vaccines Are Moving From Lab to Clinic
Personalized cancer neoantigen vaccines (PCVs) train the immune system to attack tumors using targets unique to each patient's mutations. Advances in DNA sequencing and computing have made it practical to identify these targets quickly and build tailored vaccines around them. This review from Dana-Farber Cancer Institute synthesizes the latest clinical evidence to identify which cancer types are best suited for PCVs, when in the treatment course to administer them, and how to combine them with other therapies like checkpoint inhibitors for the greatest effect. The authors also tackle remaining obstacles — manufacturing timelines, patient selection, and regulatory pathways — that must be solved before these vaccines can reach broader clinical use. The field is at an inflection point, with multiple platforms now scalable enough for widespread deployment.
